JP6670987B2 - ヒトセクレトグロビンタンパク質の修飾および新規組成物 - Google Patents

ヒトセクレトグロビンタンパク質の修飾および新規組成物 Download PDF

Info

Publication number
JP6670987B2
JP6670987B2 JP2016503333A JP2016503333A JP6670987B2 JP 6670987 B2 JP6670987 B2 JP 6670987B2 JP 2016503333 A JP2016503333 A JP 2016503333A JP 2016503333 A JP2016503333 A JP 2016503333A JP 6670987 B2 JP6670987 B2 JP 6670987B2
Authority
JP
Japan
Prior art keywords
secretoglobin
rhcc10
modified
unmodified
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016503333A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016515532A (ja
JP2016515532A5 (https=
Inventor
ピロン，アプリーレ，エル．
ハリプラカシャ，ハムチャ，ケー．
クレイトン，リチャード，エス．
ウィン，メリッサ，イー．
Original Assignee
エーピーシー リサーチ アセッツ，エルエルシー
エーピーシー リサーチ アセッツ，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エーピーシー リサーチ アセッツ，エルエルシー, エーピーシー リサーチ アセッツ，エルエルシー filed Critical エーピーシー リサーチ アセッツ，エルエルシー
Publication of JP2016515532A publication Critical patent/JP2016515532A/ja
Publication of JP2016515532A5 publication Critical patent/JP2016515532A5/ja
Application granted granted Critical
Publication of JP6670987B2 publication Critical patent/JP6670987B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyrrole Compounds (AREA)
JP2016503333A 2013-03-15 2014-03-17 ヒトセクレトグロビンタンパク質の修飾および新規組成物 Active JP6670987B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/843,773 US9394349B2 (en) 2013-03-15 2013-03-15 Modification and compositions of human secretoglobin proteins
US13/843,773 2013-03-15
PCT/US2014/030117 WO2014145368A2 (en) 2013-03-15 2014-03-17 Modification and novel compositions of human secretoglobin proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019218277A Division JP2020055833A (ja) 2013-03-15 2019-12-02 ヒトセクレトグロビンタンパク質の修飾および新規組成物

Publications (3)

Publication Number Publication Date
JP2016515532A JP2016515532A (ja) 2016-05-30
JP2016515532A5 JP2016515532A5 (https=) 2017-04-20
JP6670987B2 true JP6670987B2 (ja) 2020-03-25

Family

ID=51530119

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016503333A Active JP6670987B2 (ja) 2013-03-15 2014-03-17 ヒトセクレトグロビンタンパク質の修飾および新規組成物
JP2019218277A Pending JP2020055833A (ja) 2013-03-15 2019-12-02 ヒトセクレトグロビンタンパク質の修飾および新規組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019218277A Pending JP2020055833A (ja) 2013-03-15 2019-12-02 ヒトセクレトグロビンタンパク質の修飾および新規組成物

Country Status (13)

Country Link
US (4) US9394349B2 (https=)
EP (2) EP2968449A4 (https=)
JP (2) JP6670987B2 (https=)
KR (1) KR20160030076A (https=)
CN (1) CN105744946A (https=)
AU (1) AU2014233127A1 (https=)
BR (1) BR112015021266A2 (https=)
CA (1) CA2907439A1 (https=)
IL (1) IL241417A0 (https=)
MX (1) MX2015013092A (https=)
RU (1) RU2015144360A (https=)
SG (1) SG11201507277YA (https=)
WO (1) WO2014145368A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12162914B2 (en) 2013-03-15 2024-12-10 Apc Research Assets Llc Modification and compositions of human secretoglobin proteins
US9394349B2 (en) * 2013-03-15 2016-07-19 Therabron Therapeutics, Inc. Modification and compositions of human secretoglobin proteins
JP2018502850A (ja) * 2014-12-22 2018-02-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗原、抗体を作成するための組成物及び方法、ならびに免疫療法のための組成物及び方法
US20180325931A1 (en) 2017-01-21 2018-11-15 Ningbo Zhiming Biotechnology Co., Ltd. Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
JP2022509856A (ja) * 2018-11-30 2022-01-24 エーピーシー リサーチ アセッツ，エルエルシー ヘパラン硫酸プロテオグリカンタンパク質との相互作用を介してグリコカリックスを保護するためのセクレトグロビンの組成物及び使用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1006919A3 (nl) * 1993-03-15 1995-01-24 Ley Marc Jozef Philemon De Farmaceutisch preparaat op basis van clara celeiwit cc10, en het gebruik daarvan als geneesmiddel en diagnosticum.
US20060281681A1 (en) 1997-05-28 2006-12-14 Pilon Aprile L Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
US20040047857A1 (en) * 1997-05-28 2004-03-11 Pilon Aprile L. Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
US20030008816A1 (en) 1997-05-28 2003-01-09 Pilon Aprile L. Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
WO2000009741A1 (en) 1998-08-13 2000-02-24 The Trustees Of The University Of Pennsylvania Method of identifying proteins
US6953666B1 (en) 1998-11-06 2005-10-11 Emory University Biomarkers for oxidative stress
WO2004101824A1 (ja) 2003-05-14 2004-11-25 Shionogi & Co., Ltd. 慢性閉塞性肺疾患の検出方法
AU2004254600A1 (en) 2003-06-26 2005-01-13 Lifesensors, Inc. Methods and compositions for enhanced protein expression and purification
CN1580261A (zh) * 2003-08-06 2005-02-16 上海富纯中南生物技术有限公司 Cc10蛋白的制备及应用
JP2007511517A (ja) 2003-11-14 2007-05-10 アルザ・コーポレーシヨン 薬剤と照射を受けた賦形剤の製剤の中の薬剤の酸化を最小化
US20060275794A1 (en) 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
US8133859B2 (en) 2006-09-27 2012-03-13 The United States Of America As Represented By The Department Of Health And Human Services SCGB3A2 as a growth factor and anti-apoptotic agent
US20090004684A1 (en) 2007-05-23 2009-01-01 Claudia Susanne Maier Compositions and Methods for Detection and Quantification of Protein Oxidation
MX2012004409A (es) * 2009-10-15 2012-08-23 Clarassance Inc Proteina recombinante de humano cc10 para el tratamiento de la influenza.
US9394349B2 (en) * 2013-03-15 2016-07-19 Therabron Therapeutics, Inc. Modification and compositions of human secretoglobin proteins

Also Published As

Publication number Publication date
JP2020055833A (ja) 2020-04-09
US10676513B2 (en) 2020-06-09
CA2907439A1 (en) 2014-09-18
EP2968449A4 (en) 2017-03-22
JP2016515532A (ja) 2016-05-30
SG11201507277YA (en) 2015-10-29
US10294285B2 (en) 2019-05-21
US20140275477A1 (en) 2014-09-18
EP3403666A1 (en) 2018-11-21
AU2014233127A1 (en) 2015-09-24
WO2014145368A2 (en) 2014-09-18
US9394349B2 (en) 2016-07-19
IL241417A0 (en) 2015-11-30
BR112015021266A2 (pt) 2017-10-10
US20200325190A1 (en) 2020-10-15
US20160362462A1 (en) 2016-12-15
CN105744946A (zh) 2016-07-06
MX2015013092A (es) 2016-06-02
KR20160030076A (ko) 2016-03-16
EP2968449A2 (en) 2016-01-20
US20190337999A1 (en) 2019-11-07
WO2014145368A3 (en) 2014-11-27
RU2015144360A (ru) 2017-04-24

Similar Documents

Publication Publication Date Title
JP2020055833A (ja) ヒトセクレトグロビンタンパク質の修飾および新規組成物
Souza et al. Dityrosine cross-linking promotes formation of stable α-synuclein polymers: implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies
JP6621752B2 (ja) 変異した線維芽細胞増殖因子（ｆｇｆ）１および使用方法
Barbana et al. Interaction of bovine α-lactalbumin with fatty acids as determined by partition equilibrium and fluorescence spectroscopy
Plante et al. Characterization of recombinant murine binder of sperm protein homolog 1 and its role in capacitation
EP2435465B1 (en) Methylglyoxal-scavenging compounds and their use for the prevention and treatment of pain and/or hyperalgesia
CA2906775A1 (en) Bh4 stabilized peptides and uses thereof
Pulkki et al. The bioactivity of human bone morphogenetic protein-15 is sensitive to C-terminal modification: characterization of the purified untagged processed mature region
Pozzi et al. Regulation of matrix synthesis, remodeling and accumulation in glomerulosclerosis
Gangadhariah et al. Hydroimidazolone modification of human αA-crystallin: Effect on the chaperone function and protein refolding ability
Perdikoulis et al. Expression and characterisation of the thrombospondin type I repeats of human properdin
Tokutake et al. ALS-associated P56S-VAPB mutation restrains 3T3-L1 preadipocyte differentiation
US12162914B2 (en) Modification and compositions of human secretoglobin proteins
WO2020158491A1 (ja) インスリン分泌促進ペプチド
Staudt et al. Localization of the priming factors CAPS1 and CAPS2 in mouse sensory neurons is determined by their n-termini
Słowińska et al. Isolation, characterization and cDNA sequencing of a Kazal family proteinase inhibitor from seminal plasma of turkey (Meleagris gallopavo)
JP4348436B2 (ja) カテキン結合ペプチド
Gehling Synaptic targeting and (re-) localization of gephyrin by thiol-modifications
Moradi-Améli et al. Interaction between the antiapoptotic protein Nr-13 and cytochrome c. Antagonistic effect of the BH3 domain of Bax
TW202530243A (zh) 胜肽
AU2024347940A1 (en) Peptide
JP2012051826A (ja) 環状ペプチド及びその修飾ペプチド並びにＫｅｌｃｈ様ＥＣＨ結合タンパク質１の結合阻害物質のスクリーニング方法
Husic Binding, activation and cellular actions of teneurin C-terminal associated peptide (TCAP)-1 with its putative receptor, Latrophilin-1 (ADGRL1), in immortalized cell lines
Doan Characterization and likely role in bacterial host defense of the first bacterial alpha2-macroglobulin

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20151112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170316

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170316

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180403

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190729

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191101

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20191202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200109

R150 Certificate of patent or registration of utility model

Ref document number: 6670987

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250